Unapproved New Drugs/Misbranded: FDA Warning Letter to VasoCorp, Inc., 2026-07-09
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
On July 9, 2026, the FDA's Human Foods Program issued Warning Letter CMS #732724 to VasoCorp, Inc. (President William H. Cross III) regarding unapproved new drugs and misbranding violations for NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula. The FDA determined that website claims—including statements that products reduce nerve symptoms by ~76%, deliver nutrients to damaged nerves, and reduce pain intensity—establish the products as drugs intended to cure, mitigate, treat, or prevent disease under 21 U.S.C. § 321(g)(1)(B), and that they lack FDA approval as required under 21 U.S.C. § 355(a), and fail to bear adequate directions for safe use under 21 U.S.C. § 352(f)(1). VasoCorp was directed to respond within 15 working days with corrective actions or explanation, with notice that failure to do so may result in seizure and injunction.
Argus analysis
# FDA Warning Letter Analysis: VasoCorp, Inc.
**Company and Findings**
VasoCorp, Inc., based in Hiram, Georgia, received a warning letter from FDA's Human Foods Program on July 9, 2026 (CMS #732724). The agency reviewed the company's website in March 2026 and identified two products—NeuropAWAY Nerve Support Formula and NeuropAWAY PM Nighttime Nerve Support Formula—being marketed with claims that violate federal drug law. The products are marketed as dietary supplements but FDA determined the website claims establish them as drugs intended to treat, mitigate, or prevent disease, particularly peripheral neuropathy symptoms.
**Regulatory Citations and Implications**
FDA cited violations of 21 CFR 201(g)(1)(B) and 21 CFR 321(p), which define drugs and establish that unapproved new drugs cannot be legally sold. The agency also cited 21 CFR 502(f)(1) regarding misbranding—specifically that the products lack adequate directions for safe use by consumers. The cited claims include statements that the formula "reduces symptoms of burning, tingling, and numbness," "improves blood supply to damaged nerves," and "protects nerves from damage." These statements cross the line from dietary supplement structure-function claims into disease claims requiring FDA approval before marketing.
**Response Timeline and Next Steps**
VasoCorp had 15 working days from receipt to respond in writing with corrective actions or provide evidence the products don't violate law. Industry observers should monitor whether the company reformulates marketing language to remove disease claims, discontinues the products, or pursues a new drug application—an expensive and time-intensive process. Failure to respond adequately exposes VasoCorp to seizure and injunction actions.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER VasoCorp, Inc. MARCS-CMS 732724 — July 09, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Dietary Supplements Recipient: Recipient Name Mr. William H. Cross III Recipient Title President and CEO VasoCorp, Inc. 808 Metromont Rd Ste 100 Hiram , GA 30141-3056 United States Issuing Office: Human Foods Program United States July 9, 2026 WARNING LETTER CMS #732724 (b)(4) Dear Mr. Cross: This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.vasocorp.com in March 2026 and has determined that you take orders there for the products NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov. Examples of some of the claims that provide evidence that your products are intended for use as drugs include: NeuropAWAY – Nerve Support Formula “NeuropAWAY Nerve Support Formula is a patented formula that is clinically proven to reduce the overall symptoms of occasional burning, tingling, and numbness by ~76%. NeuropAWAY’s synergistic formula combines Taurine with other key ingredients to improve blood supply to damaged and needy nerves.” “NeuropAWAY Nerve Support 60 Daily Capsules Delivers Key Nutrients to Damaged & Inflamed Nerves.” (www.vasocorp.com) “Consumption of NeuropAWAY resulted in a signification reduction [Pain] in PI-NRS after 7 days of consumption.” Note: PI-NRS is Pain Intensity Numerical Rating Scale. (https://www.vasocorp.com/products/neuropaway-capsules) “VasoCorp was founded by William Cross, a Type 1 diabetic driven by his personal quest for relief from nerve discomfort. After years of dedicated research, William developed the unique formula for our flagship product, NeuropAWAY Nerve Support Formula. . . . You can find NeuropAWAY products in the diabetes section of major pharmacies across the country . . ..” (https://www.vasocorp.com/pages/about-us) NeuropAWAY pm – Nighttime Nerve Support Formula “NeuropAWAY targets the cause of neuropathic pains in: head & neck, feet, static nerve, hands, arms, legs…” “NeuropAWAY burning, tingling, & numbness support.” “Supports damaged and needy nerves.” (https://www.vasocorp.com/products/neuropaway-pm) NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula “R-Alpha Lipoic Acid (ALA) Protect nerves from damage…” R-Alpha Lipoic Acid is an ingredient in both the NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to VasoCorp, Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vasocorp-inc-732724-07092026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Unapproved New Drugs/Misbranded: FDA Warning Letter to VasoCorp, Inc., 2026-07-09. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-vasocorp-inc-2026-07-09-unapproved-drug
"Unapproved New Drugs/Misbranded: FDA Warning Letter to VasoCorp, Inc., 2026-07-09." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-vasocorp-inc-2026-07-09-unapproved-drug.
Argus HQ Research. "Unapproved New Drugs/Misbranded: FDA Warning Letter to VasoCorp, Inc., 2026-07-09." Digital Empire Holdings LLC. Accessed July 29, 2026. https://argushq.ai/fda/warning-letter/fda-wl-vasocorp-inc-2026-07-09-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_vasocorp_inc_2026_07_09_unapproved_drug_2026,
title = {Unapproved New Drugs/Misbranded: FDA Warning Letter to VasoCorp, Inc., 2026-07-09},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-vasocorp-inc-2026-07-09-unapproved-drug},
note = {Accessed: July 29, 2026}
}